Hormonaly.ai Opens Clinical AI API to Enterprise Buyers as FDA Peptide Review Reshapes Compounding

Hormonaly.ai, an FHS Capital portfolio company, launches tiered enterprise API access to its clinical AI platform for metabolic and longevity medicine — with 400 practitioners and 10 enterprise customers already onboard.